Nothing Special   »   [go: up one dir, main page]

WO2022023292A3 - Corona virus spike protein-targeting antibodies and use thereof - Google Patents

Corona virus spike protein-targeting antibodies and use thereof Download PDF

Info

Publication number
WO2022023292A3
WO2022023292A3 PCT/EP2021/070904 EP2021070904W WO2022023292A3 WO 2022023292 A3 WO2022023292 A3 WO 2022023292A3 EP 2021070904 W EP2021070904 W EP 2021070904W WO 2022023292 A3 WO2022023292 A3 WO 2022023292A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
antibodies
domain
infection
spike
Prior art date
Application number
PCT/EP2021/070904
Other languages
French (fr)
Other versions
WO2022023292A9 (en
WO2022023292A2 (en
Inventor
Hans-Martin JÄCK
Klaus Überla
Thomas Winkler
Original Assignee
Friedrich-Alexander-Universität Erlangen-Nürnberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friedrich-Alexander-Universität Erlangen-Nürnberg filed Critical Friedrich-Alexander-Universität Erlangen-Nürnberg
Publication of WO2022023292A2 publication Critical patent/WO2022023292A2/en
Publication of WO2022023292A3 publication Critical patent/WO2022023292A3/en
Publication of WO2022023292A9 publication Critical patent/WO2022023292A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antibodies that bind to the spike (S) protein of the new coronavirus CoV-2 are provided. Some of them bind to the N-terminal domain (NTD), the receptor-binding domain (RBD), the S2 domain, the S1 domain or the trimeric spike ectodomain. Some antibodies inhibit the binding of the CoV-2 spike protein to the human angiotensin-converting enzyme 2 (hACE- 2). Preferably the antibodies neutralize and prevent CoV-2 infection of cells and animals. Also provided are hybridoma cell lines that produce, and most preferably, secrete into cell culture media the antibodies of the invention. Also provided are eukaryotic expression vectors that encode fully human CoV-2 neutralizing antibodies. The antibodies of the invention are useful for diagnosing and treating disorders associated with CoV-2 infections and for preventing symptoms of a CoV-2 infection as well as CoV-2 infection as such.
PCT/EP2021/070904 2020-07-31 2021-07-26 Corona virus spike protein-targeting antibodies and use thereof WO2022023292A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20189025 2020-07-31
EP20189025.8 2020-07-31
EP21157721.8 2021-02-17
EP21157721 2021-02-17

Publications (3)

Publication Number Publication Date
WO2022023292A2 WO2022023292A2 (en) 2022-02-03
WO2022023292A3 true WO2022023292A3 (en) 2022-03-10
WO2022023292A9 WO2022023292A9 (en) 2022-05-05

Family

ID=77300889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/070904 WO2022023292A2 (en) 2020-07-31 2021-07-26 Corona virus spike protein-targeting antibodies and use thereof

Country Status (1)

Country Link
WO (1) WO2022023292A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225098A1 (en) * 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US10881084B2 (en) 2010-07-26 2021-01-05 Trianni, Inc Transgenic animals and methods of use
JP5782185B2 (en) 2012-06-01 2015-09-24 日本電信電話株式会社 Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "FAU scientists are working on a vaccine against Covid-19", 23 April 2020 (2020-04-23), XP055859170, Retrieved from the Internet <URL:https://www.research-in-germany.org/news/2020/4/2020-04-23_FAU_scientists_are_working_on_a_vaccine_against_Covid-19.html> [retrieved on 20211109] *
CAO YUNLONG ET AL: "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 1, 18 May 2020 (2020-05-18), pages 73, XP086211425, ISSN: 0092-8674, [retrieved on 20200518], DOI: 10.1016/J.CELL.2020.05.025 *
CAO YUNLONG: "Supplemental Information Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients B Cells", 18 May 2020 (2020-05-18), XP055746477, Retrieved from the Internet <URL:https://ars.els-cdn.com/content/image/1-s2.0-S0092867420306206-mmc3.pdf> [retrieved on 20201103] *
HANSEN JOHANNA ET AL: "Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail", SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE), 15 June 2020 (2020-06-15), United States, pages 1010 - 1014, XP055834409, Retrieved from the Internet <URL:https://www.science.org/doi/pdf/10.1126/science.abd0827?casa_token=_vEIzVci8JQAAAAA:OYz2MUNaZ56ufrJZMlQ4Psz8KEgqAZN-93rqmHms7hgKbSjB8txQM4yWwYNkq8i7pNt2-Vc18N_waBM> [retrieved on 20210824], DOI: 10.1126/science.abd0827 *
LIU LIHONG ET AL: "Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 584, no. 7821, 22 July 2020 (2020-07-22), pages 450 - 456, XP037223585, ISSN: 0028-0836, [retrieved on 20200722], DOI: 10.1038/S41586-020-2571-7 *
MENG YUAN ET AL: "A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV", SCIENCE, vol. 368, no. 6491, 8 May 2020 (2020-05-08), pages 630 - 633, XP055707792, DOI: 10.1126/science.abb7269 *
SHI RUI ET AL: "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 584, no. 7819, 26 May 2020 (2020-05-26), pages 120 - 124, XP037211681, ISSN: 0028-0836, [retrieved on 20200526], DOI: 10.1038/S41586-020-2381-Y *
WAN JINKAI ET AL: "Human IgG cell neutralizing monoclonal antibodies blockSARS-CoV-2 infection", BIORXIV, 28 May 2020 (2020-05-28), XP055773469, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.05.19.104117v2.full.pdf> [retrieved on 20210208], DOI: 10.1101/2020.05.19.104117 *
WAN JINKAI ET AL: "Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection", CELL REPORTS, vol. 32, no. 3, 3 July 2020 (2020-07-03), US, pages 107918, XP055773465, ISSN: 2211-1247, Retrieved from the Internet <URL:https://www.cell.com/cell-reports/pdf/S2211-1247(20)30899-8.pdf> DOI: 10.1016/j.celrep.2020.107918 *
YAN WU ET AL: "A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2", SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE), 13 May 2020 (2020-05-13), United States, pages 1274 - 1278, XP055758869, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/368/6496/1274.full.pdf> DOI: 10.1126/science.abc2241 *
YAN WU ET AL: "Supplementary Material - A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2", SCIENCE, vol. 368, no. 6496, 13 May 2020 (2020-05-13), US, pages 1274 - 1278, XP055799109, ISSN: 0036-8075, Retrieved from the Internet <URL:https://science.sciencemag.org/highwire/filestream/744452/field_highwire_adjunct_files/1/abc2241_Wu_SM.pdf> DOI: 10.1126/science.abc2241 *

Also Published As

Publication number Publication date
WO2022023292A9 (en) 2022-05-05
WO2022023292A2 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
AU2016249140A8 (en) Anti-PACAP antibodies and uses thereof
MX2007001638A (en) Binding domain fusion proteins.
WO2019035880A8 (en) Purified mesenchymal stem cell exosomes and uses thereof
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2011013133A3 (en) Novel biopesticide compositions and method for isolation and characterization of same
WO2021226553A3 (en) April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
WO2020169755A3 (en) Antibodies
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
EA200601894A1 (en) DERIVATIVES OF PIPERASINILIPIPERIDINE AS ANTAGONISTS OF CHEMOKINE RECEPTOR
WO2022023292A3 (en) Corona virus spike protein-targeting antibodies and use thereof
BR112022015858A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS TO TREAT A DISORDER ASSOCIATED WITH P2X3 ACTIVITY, TO TREAT PAIN, TO TREAT A URINARY TRACT DISORDER, TO REDUCE OR PREVENT UNCONTROLLED URINE LOSS, TO TREAT COUGH, TO TREAT ITCH, AND TO TREAT Endometriosis, pain associated with endometriosis and symptoms associated with endometriosis
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
Erickson et al. The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
CL2022001655A1 (en) Engineered variants of acid alpha-glucosidase.
WO2022184854A3 (en) Formulations of ace2 fc fusion proteins
DK1567018T3 (en) Method for Improving Immune Function in Mammals Using Lactobacillus Reuteri Strains
MX2022009784A (en) Anti-bcma therapy in autoimmune disorders.
WO2021216876A3 (en) Antibodies to coronavirus spike protein and methods of use thereof
WO2006021954A3 (en) Peptide inhibitors for mediating stress responses
WO2022200291A3 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
BR112023000422A2 (en) METHODS TO IDENTIFY CORONAVIRUS CROSS-REACING ANTIBODIES
Rupprecht et al. Adhesion of Borrelia garinii to neuronal cells is mediated by the interaction of OspA with proteoglycans
WO2022031940A3 (en) Il28ra binding molecules and methods of use
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21752653

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21752653

Country of ref document: EP

Kind code of ref document: A2